Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 50 articles: HTML format

Single Articles

July 2025
1. BURTON EM, Milton DR, Tetzlaff MT, Wani K, et al
   Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
   J Clin Oncol. 2025 Jul 10:JCO2500494. doi: 10.1200/JCO-25-00494.
   PubMed     Abstract available
   
   
   
2. WONG MK, Milhem MM, Sacco JJ, Michels J, et al
   RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
   J Clin Oncol. 2025 Jul 8:101200JCO2501346. doi: 10.1200/JCO-25-01346.
   PubMed     Abstract available
   
   
   June 2025
3. MARQUEZ-RODAS I, Dutriaux C, Saiag P, de la Cruz Merino L, et al
   BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
   J Clin Oncol. 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595.
   PubMed     Abstract available
   
   
   
4. DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al
   Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
   J Clin Oncol. 2025 Jun 25:JCO2501412. doi: 10.1200/JCO-25-01412.
   PubMed    
   
   
   
5. MCCLELLAND PH, Nah SK, Gustafson AM, Dinerman AJ, et al
   Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma.
   J Clin Oncol. 2025 Jun 13:JCO2402348. doi: 10.1200/JCO-24-02348.
   PubMed     Abstract available
   
   
   
6. LODDE GC, Hassel JC, von Wasielewski I, Meier F, et al
   Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients.
   J Clin Oncol. 2025 Jun 3:101200JCO2402776. doi: 10.1200/JCO-24-02776.
   PubMed     Abstract available
   
   
   
7. MEDINA T, Chesney JA, Kluger HM, Hamid O, et al
   Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
   J Clin Oncol. 2025 Jun 2:101200JCO2500765. doi: 10.1200/JCO-25-00765.
   PubMed     Abstract available
   
   
   April 2025
8. SPERDUTO PW, Marqueen KE, Chang E, Li J, et al
   Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.
   J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351.
   PubMed     Abstract available
   
   
   March 2025
9. LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al
   Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
   J Clin Oncol. 2025 Mar 7:JCO2500452. doi: 10.1200/JCO-25-00452.
   PubMed    
   
   
   
10. DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al
    Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
    J Clin Oncol. 2025 Mar 6:JCO2400727. doi: 10.1200/JCO.24.00727.
    PubMed     Abstract available
    
    
    
11. WEISS SA, Djureinovic D, Wei W, Tran T, et al
    Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
    J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219.
    PubMed     Abstract available
    
    
    February 2025
12. PATEL SP, Sheth RA, Davis C, Medina T, et al
    Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.
    J Clin Oncol. 2025 Feb 6:JCO2401802. doi: 10.1200/JCO-24-01802.
    PubMed     Abstract available
    
    
    January 2025
13. ROTZ SJ, Stratton K, Leisenring WM, Smith SA, et al
    Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2025 Jan 8:JCO2401519. doi: 10.1200/JCO-24-01519.
    PubMed     Abstract available
    
    
    
14. HUANG RY, Youssef G, Nelson T, Wen PY, et al
    Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953.
    PubMed     Abstract available
    
    
    December 2024
15. TAWBI HA, Hodi FS, Lipson EJ, Schadendorf D, et al
    Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
    J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124.
    PubMed     Abstract available
    
    
    November 2024
16. LONG GV, Larkin J, Schadendorf D, Grob JJ, et al
    Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
    J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400.
    PubMed     Abstract available
    
    
    
17. KREFT S, Lorigan P
    Combination Immunotherapy for Advanced Melanoma-How to Choose?
    J Clin Oncol. 2024 Nov 4:JCO2402005. doi: 10.1200/JCO-24-02005.
    PubMed    
    
    
    
18. VERHEIJDEN RJ, de Groot JS, Fabriek BO, Hew MN, et al
    Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.
    J Clin Oncol. 2024;42:3713-3724.
    PubMed     Abstract available
    
    
    October 2024
19. WEBER JS, Middleton MR, Yates G, Sharpe DJ, et al
    Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
    J Clin Oncol. 2024 Oct 8:JCO2400237. doi: 10.1200/JCO.24.00237.
    PubMed     Abstract available
    
    
    
20. SCHMITT AM, Larkin J, Patel SP
    Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out.
    J Clin Oncol. 2024 Oct 7:JCO2401572. doi: 10.1200/JCO-24-01572.
    PubMed     Abstract available
    
    
    
21. MARGOLIN KA
    Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies?
    J Clin Oncol. 2024 Oct 7:JCO2401634. doi: 10.1200/JCO-24-01634.
    PubMed    
    
    
    
22. SARGEN MR, Barnhill RL, Elder DE, Swetter SM, et al
    Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.
    J Clin Oncol. 2024 Oct 4:JCO2401154. doi: 10.1200/JCO.24.01154.
    PubMed     Abstract available
    
    
    September 2024
23. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
    J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
    PubMed     Abstract available
    
    
    August 2024
24. LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al
    First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
    J Clin Oncol. 2024 Aug 13:JCO2401125. doi: 10.1200/JCO.24.01125.
    PubMed     Abstract available
    
    
    
25. WEBER J, Del Vecchio M, Mandala M, Gogas H, et al
    Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
    J Clin Oncol. 2024 Aug 5:JCO2301448. doi: 10.1200/JCO.23.01448.
    PubMed     Abstract available
    
    
    July 2024
26. HARBOUR JW, Correa ZM, Schefler AC, Mruthyunjaya P, et al
    15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
    J Clin Oncol. 2024 Jul 25:JCO2400447. doi: 10.1200/JCO.24.00447.
    PubMed     Abstract available
    
    
    June 2024
27. HAMID O, Lewis KD, Weise A, McKean M, et al
    Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
    J Clin Oncol. 2024 Jun 20:JCO2302172. doi: 10.1200/JCO.23.02172.
    PubMed     Abstract available
    
    
    March 2024
28. SCHENK KM, Deutsch JS, Chandra S, Davar D, et al
    Nivolumab + Tacrolimus + Prednisone +/- Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    J Clin Oncol. 2024;42:1011-1020.
    PubMed     Abstract available
    
    
    
29. LUKE JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, et al
    Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
    J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355.
    PubMed     Abstract available
    
    
    February 2024
30. 
    Expression of Concern: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
    J Clin Oncol. 2024 Feb 23:JCO2400161. doi: 10.1200/JCO.24.00161.
    PubMed    
    
    
    
31. VAREY AHR, Li I, El Sharouni MA, Simon J, et al
    Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
    J Clin Oncol. 2024 Feb 5:JCO2301020. doi: 10.1200/JCO.23.01020.
    PubMed     Abstract available
    
    
    
32. 
    Erratum: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
    J Clin Oncol. 2024 Feb 1:JCO2400017. doi: 10.1200/JCO.24.00017.
    PubMed    
    
    
    December 2023
33. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    September 2023
34. 
    Erratum: Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2023 Sep 18:JCO2301773. doi: 10.1200/JCO.23.01773.
    PubMed    
    
    
    August 2023
35. DIAB A, Gogas H, Sandhu S, Long GV, et al
    Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
    J Clin Oncol. 2023 Aug 31:JCO2300172. doi: 10.1200/JCO.23.00172.
    PubMed     Abstract available
    
    
    
36. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    PubMed     Abstract available
    
    
    
37. SETH R, Agarwala SS, Messersmith H, Alluri KC, et al
    Systemic Therapy for Melanoma: ASCO Guideline Update.
    J Clin Oncol. 2023 Aug 14:JCO2301136. doi: 10.1200/JCO.23.01136.
    PubMed     Abstract available
    
    
    
38. 
    Retraction: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    J Clin Oncol. 2023 Aug 11:JCO2301358. doi: 10.1200/JCO.23.01358.
    PubMed    
    
    
    July 2023
39. ASCIERTO PA, Dummer R, Gogas HJ, Arance A, et al
    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
    J Clin Oncol. 2023 Jul 28:JCO2202322. doi: 10.1200/JCO.22.02322.
    PubMed     Abstract available
    
    
    
40. ZHANG X, Ferris L, Faries MB, Luke JJ, et al
    Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
    J Clin Oncol. 2023 Jul 6:JCO2300255. doi: 10.1200/JCO.23.00255.
    PubMed    
    
    
    June 2023
41. ROBERT C, Carlino MS, McNeil C, Ribas A, et al
    Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
    J Clin Oncol. 2023 Jun 22:JCO2201599. doi: 10.1200/JCO.22.01599.
    PubMed     Abstract available
    
    
    
42. OLSON DJ, Odunsi K
    Adoptive Cell Therapy for Nonhematologic Solid Tumors.
    J Clin Oncol. 2023;41:3397-3407.
    PubMed     Abstract available
    
    
    
43. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    PubMed     Abstract available
    
    
    
44. RIELY GJ, Smit EF, Ahn MJ, Felip E, et al
    Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300774. doi: 10.1200/JCO.23.00774.
    PubMed     Abstract available
    
    
    April 2023
45. LONG GV, Menzies AM, Scolyer RA
    Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    J Clin Oncol. 2023 Apr 27:JCO2202575. doi: 10.1200/JCO.22.02575.
    PubMed     Abstract available
    
    
    March 2023
46. DE BRAUD F, Dooms C, Heist RS, Lebbe C, et al
    Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
    J Clin Oncol. 2023 Mar 22:JCO2202018. doi: 10.1200/JCO.22.02018.
    PubMed     Abstract available
    
    
    
47. PHADKE MS, Smalley KSM
    Targeting NRAS Mutations in Advanced Melanoma.
    J Clin Oncol. 2023 Mar 22:JCO2300205. doi: 10.1200/JCO.23.00205.
    PubMed    
    
    
    
48. OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al
    Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705.
    PubMed     Abstract available
    
    
    
49. 
    Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed CellDeath Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2023 Mar 20:JCO2300439. doi: 10.1200/JCO.23.00439.
    PubMed    
    
    
    
50. 
    Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.